首页 > 最新文献

Digestive Surgery最新文献

英文 中文
Early Identification of Patients with Potential Failure of Nonoperative Management for Gastroduodenal Peptic Ulcer Perforation. 胃十二指肠消化性溃疡穿孔非手术治疗失败患者的早期识别。
IF 2.7 3区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-01-01 Epub Date: 2023-11-25 DOI: 10.1159/000535520
Toshimichi Kobayashi, Satoshi Tabuchi, Itsuki Koganezawa, Masashi Nakagawa, Kei Yokozuka, Shigeto Ochiai, Takahiro Gunji, Yosuke Ozawa, Toru Sano, Koichi Tomita, Naokazu Chiba, Eiji Hidaka, Shigeyuki Kawachi

Introduction: We aimed to identify objective factors associated with failure of nonoperative management (NOM) of gastroduodenal peptic ulcer perforation (GDUP) and establish a scoring model for early identification of patients in whom NOM of GDUP may fail.

Methods: A total of 71 patients with GDUP were divided into NOM (cases of NOM success) and operation groups (cases requiring emergency operation or conversion from NOM to operation). Using logistic regression analysis, a scoring model was established based on the independent factors. The patients were stratified into low-risk and high-risk groups according to the scores.

Results: Of the 71 patients, 18 and 53 were in the NOM and operation groups, respectively. Ascites in the pelvic cavity on computed tomography (CT) and sequential organ failure assessment (SOFA) score at admission were identified as independent factors for NOM failure. The scoring model was established based on the presence of ascites in the pelvic cavity on CT and SOFA score ≥2 at admission. The operation rates for GDUP were 28.6% and 86.0% in the low-risk (score, 0) and high-risk groups (scores, 2 and 4), respectively.

Conclusion: Our scoring model may help determine NOM failure or success in patients with GDUP and make decisions regarding initial treatment.

前言:我们旨在确定与胃十二指肠消化性溃疡穿孔(GDUP)非手术治疗失败(NOM)相关的客观因素,并建立一个评分模型,用于早期识别GDUP非手术治疗失败的患者。方法:将71例GDUP患者分为NOM组(NOM成功病例)和手术组(需要紧急手术或由NOM转为手术病例)。采用logistic回归分析,建立了基于独立因素的评分模型。根据评分将患者分为低危组和高危组。结果:71例患者中,NOM组18例,手术组53例。入院时计算机断层扫描(CT)盆腔腹水和顺序器官衰竭评估(SOFA)评分被确定为NOM失败的独立因素。以入院时CT显示盆腔腹水及SOFA评分≥2为评分标准建立评分模型。低危组(评分0分)和高危组(评分2分和4分)GDUP手术率分别为28.6%和86.0%。结论:我们的评分模型可以帮助确定GDUP患者的NOM失败或成功,并决定初始治疗。
{"title":"Early Identification of Patients with Potential Failure of Nonoperative Management for Gastroduodenal Peptic Ulcer Perforation.","authors":"Toshimichi Kobayashi, Satoshi Tabuchi, Itsuki Koganezawa, Masashi Nakagawa, Kei Yokozuka, Shigeto Ochiai, Takahiro Gunji, Yosuke Ozawa, Toru Sano, Koichi Tomita, Naokazu Chiba, Eiji Hidaka, Shigeyuki Kawachi","doi":"10.1159/000535520","DOIUrl":"10.1159/000535520","url":null,"abstract":"<p><strong>Introduction: </strong>We aimed to identify objective factors associated with failure of nonoperative management (NOM) of gastroduodenal peptic ulcer perforation (GDUP) and establish a scoring model for early identification of patients in whom NOM of GDUP may fail.</p><p><strong>Methods: </strong>A total of 71 patients with GDUP were divided into NOM (cases of NOM success) and operation groups (cases requiring emergency operation or conversion from NOM to operation). Using logistic regression analysis, a scoring model was established based on the independent factors. The patients were stratified into low-risk and high-risk groups according to the scores.</p><p><strong>Results: </strong>Of the 71 patients, 18 and 53 were in the NOM and operation groups, respectively. Ascites in the pelvic cavity on computed tomography (CT) and sequential organ failure assessment (SOFA) score at admission were identified as independent factors for NOM failure. The scoring model was established based on the presence of ascites in the pelvic cavity on CT and SOFA score ≥2 at admission. The operation rates for GDUP were 28.6% and 86.0% in the low-risk (score, 0) and high-risk groups (scores, 2 and 4), respectively.</p><p><strong>Conclusion: </strong>Our scoring model may help determine NOM failure or success in patients with GDUP and make decisions regarding initial treatment.</p>","PeriodicalId":11241,"journal":{"name":"Digestive Surgery","volume":" ","pages":"24-29"},"PeriodicalIF":2.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138440449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Use of Acetylcholinesterase Inhibitors in Reducing Time to Gastrointestinal Function Recovery following Abdominal Surgery: A Systematic Review. 使用乙酰胆碱酯酶抑制剂缩短腹部手术后胃肠功能恢复的时间:系统综述。
IF 2.7 3区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-01-01 Epub Date: 2023-12-13 DOI: 10.1159/000535753
Luke Traeger, Nagendra Dudi-Venkata, Sergei Bedrikovetski, Hidde M Kroon, James W Moore, Tarik Sammour

Introduction: Postoperative ileus (POI) is a significant complication following abdominal surgery, increasing morbidity and mortality. The cholinergic anti-inflammatory response is one of the major pathways involved in developing POI, but current recommendations to prevent POI do not target this. This review aims to summarise evidence for the use of acetylcholinesterase inhibitors, neostigmine and pyridostigmine, to reduce the time to return of gastrointestinal function (GI) following abdominal surgery.

Methods: A systematic search of various databases was performed from 1946 to May 2023. Randomised controlled trials (RCTs) on acetylcholinesterase inhibitors in intra-abdominal surgery were included. Data on time to flatus and/or stool and side effects were extracted.

Results: Among 776 screened manuscripts, 8 RCTs (703 patients) investigating acetylcholinesterase inhibitors in intra-abdominal surgery were analysed. Five studies showed a significant reduction in time to flatus and/or stool by 17-47.6 h. Methodological variations, differing procedure types, and potential bias were observed. Limited studies reported side effects or length of stay.

Conclusion: Acetylcholinesterase inhibitors may reduce the time for GI to return. However, current evidence is limited and biased. Further studies incorporating acetylcholinesterase inhibitors in an enhanced recovery protocol are required to address this question, especially for patients undergoing colorectal surgery.

导言:术后回肠梗阻(POI)是腹部手术后的一种重要并发症,会增加发病率和死亡率。胆碱能抗炎反应是发生 POI 的主要途径之一,但目前预防 POI 的建议并不以胆碱能抗炎反应为目标。本综述旨在总结使用乙酰胆碱酯酶抑制剂、新斯的明和吡啶斯的明缩短腹部手术后胃肠功能恢复时间的证据:方法:对 1946 年至 2023 年 5 月期间的各种数据库进行了系统检索。方法:对 1946 年至 2023 年 5 月期间的各种数据库进行了系统检索,纳入了有关乙酰胆碱酯酶抑制剂在腹腔内手术中应用的随机对照试验(RCT)。结果:在筛选出的 776 篇手稿中,对 8 项研究乙酰胆碱酯酶抑制剂在腹腔内手术中应用的 RCT(703 名患者)进行了分析。五项研究显示,排气和/或排便时间明显缩短了 17-47.6 小时。研究中发现了方法上的差异、不同的手术类型以及潜在的偏差。有限的研究报告了副作用或住院时间:结论:乙酰胆碱酯酶抑制剂可缩短胃肠功能恢复时间。结论:乙酰胆碱酯酶抑制剂可缩短胃肠功能恢复时间,但目前的证据有限且存在偏差。需要进一步研究将乙酰胆碱酯酶抑制剂纳入增强恢复方案,以解决这一问题,尤其是针对接受结直肠手术的患者。
{"title":"Use of Acetylcholinesterase Inhibitors in Reducing Time to Gastrointestinal Function Recovery following Abdominal Surgery: A Systematic Review.","authors":"Luke Traeger, Nagendra Dudi-Venkata, Sergei Bedrikovetski, Hidde M Kroon, James W Moore, Tarik Sammour","doi":"10.1159/000535753","DOIUrl":"10.1159/000535753","url":null,"abstract":"<p><strong>Introduction: </strong>Postoperative ileus (POI) is a significant complication following abdominal surgery, increasing morbidity and mortality. The cholinergic anti-inflammatory response is one of the major pathways involved in developing POI, but current recommendations to prevent POI do not target this. This review aims to summarise evidence for the use of acetylcholinesterase inhibitors, neostigmine and pyridostigmine, to reduce the time to return of gastrointestinal function (GI) following abdominal surgery.</p><p><strong>Methods: </strong>A systematic search of various databases was performed from 1946 to May 2023. Randomised controlled trials (RCTs) on acetylcholinesterase inhibitors in intra-abdominal surgery were included. Data on time to flatus and/or stool and side effects were extracted.</p><p><strong>Results: </strong>Among 776 screened manuscripts, 8 RCTs (703 patients) investigating acetylcholinesterase inhibitors in intra-abdominal surgery were analysed. Five studies showed a significant reduction in time to flatus and/or stool by 17-47.6 h. Methodological variations, differing procedure types, and potential bias were observed. Limited studies reported side effects or length of stay.</p><p><strong>Conclusion: </strong>Acetylcholinesterase inhibitors may reduce the time for GI to return. However, current evidence is limited and biased. Further studies incorporating acetylcholinesterase inhibitors in an enhanced recovery protocol are required to address this question, especially for patients undergoing colorectal surgery.</p>","PeriodicalId":11241,"journal":{"name":"Digestive Surgery","volume":" ","pages":"12-23"},"PeriodicalIF":2.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10946644/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138800984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of Treatment Strategies and Survival of Patients with cT4bM0 Esophageal Cancer: A Nationwide Cohort Study. 评估 cT4bM0 食管癌患者的治疗策略和生存率:一项全国性队列研究。
IF 1.8 3区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-01-01 Epub Date: 2024-08-17 DOI: 10.1159/000540214
Jingpu Wang, Eline M de Groot, Zhouqiao Wu, Rob H A Verhoeven, Nadia Haj Mohammad, Stella Mook, Lucas Goense, Sheraz R Markar, Jelle P Ruurda, Richard van Hillegersberg

Introduction: The optimal therapeutic strategy for patients with cT4bM0 esophageal cancer is controversial and varies internationally. This study aimed to describe treatment and survival of patients with cT4bM0 esophageal cancer in the Netherlands.

Methods: Patients staged with cT4bM0 esophageal cancer who were registered in the Netherlands Cancer Registry (NCR) were included. All patients were categorized by the treatment modality received. The Kaplan-Meier method was used to estimate the overall survival of them.

Results: Between 2015 and 2020, 286 patients with cT4bM0 esophageal cancer were included. Treatment consisted of preoperative chemoradiotherapy/chemotherapy followed by surgery (8%), chemoradiotherapy alone (35%), chemotherapy alone (6%), radiotherapy alone (19%), and best supportive care (32%). The median follow-up was 28.1 months. The 1-, 3-, and 5-year survival rates of each group were 82%, 58%, 49% for preoperative therapy plus surgery; 53%, 27%, 16% for chemoradiotherapy only; 13%, 0%, 0% for chemotherapy only; 13%, 0%, 0% for radiotherapy only; and 5%, 0%, 0% for best supportive care.

Conclusion: In a selected group of patients, preoperative therapy followed by esophagectomy may lead to improved survival, which is comparable to patients with <cT4bM0 tumors. Therefore, reevaluation following chemo(radio)therapy is recommended in these patients to evaluate the possibility of additional surgical resection.

背景:cT4bM0食管癌患者的最佳治疗策略在国际上存在争议和差异。本研究旨在描述荷兰 cT4bM0 食管癌患者的治疗和生存情况:方法:纳入在荷兰癌症登记处(NCR)登记的 cT4bM0 食管癌患者。所有患者均按接受的治疗方式分类。结果:结果:2015-2020年间,共纳入286名cT4bM0食管癌患者。治疗方法包括术前化疗/化疗后手术(8%)、单纯化疗(35%)、单纯化疗(6%)、单纯放疗(19%)和最佳支持治疗(32%)。中位随访时间为 28.1 个月。各组的 1 年、3 年和 5 年生存率分别为:82%、58%、49%:术前治疗加手术的生存率分别为82%、58%、49%;仅化疗放疗的生存率分别为53%、27%、16%;仅化疗的生存率分别为13%、0%、0%;仅放疗的生存率分别为13%、0%、0%;最佳支持治疗的生存率分别为5%、0%、0%:在部分患者中,术前治疗后进行食管切除术可能会提高患者的生存率,其生存率与<cT4bM0肿瘤患者相当。因此,建议对这些患者进行化疗(放疗)后的重新评估,以评估是否有可能进行额外的手术切除。
{"title":"Evaluation of Treatment Strategies and Survival of Patients with cT4bM0 Esophageal Cancer: A Nationwide Cohort Study.","authors":"Jingpu Wang, Eline M de Groot, Zhouqiao Wu, Rob H A Verhoeven, Nadia Haj Mohammad, Stella Mook, Lucas Goense, Sheraz R Markar, Jelle P Ruurda, Richard van Hillegersberg","doi":"10.1159/000540214","DOIUrl":"10.1159/000540214","url":null,"abstract":"<p><strong>Introduction: </strong>The optimal therapeutic strategy for patients with cT4bM0 esophageal cancer is controversial and varies internationally. This study aimed to describe treatment and survival of patients with cT4bM0 esophageal cancer in the Netherlands.</p><p><strong>Methods: </strong>Patients staged with cT4bM0 esophageal cancer who were registered in the Netherlands Cancer Registry (NCR) were included. All patients were categorized by the treatment modality received. The Kaplan-Meier method was used to estimate the overall survival of them.</p><p><strong>Results: </strong>Between 2015 and 2020, 286 patients with cT4bM0 esophageal cancer were included. Treatment consisted of preoperative chemoradiotherapy/chemotherapy followed by surgery (8%), chemoradiotherapy alone (35%), chemotherapy alone (6%), radiotherapy alone (19%), and best supportive care (32%). The median follow-up was 28.1 months. The 1-, 3-, and 5-year survival rates of each group were 82%, 58%, 49% for preoperative therapy plus surgery; 53%, 27%, 16% for chemoradiotherapy only; 13%, 0%, 0% for chemotherapy only; 13%, 0%, 0% for radiotherapy only; and 5%, 0%, 0% for best supportive care.</p><p><strong>Conclusion: </strong>In a selected group of patients, preoperative therapy followed by esophagectomy may lead to improved survival, which is comparable to patients with &lt;cT4bM0 tumors. Therefore, reevaluation following chemo(radio)therapy is recommended in these patients to evaluate the possibility of additional surgical resection.</p>","PeriodicalId":11241,"journal":{"name":"Digestive Surgery","volume":" ","pages":"171-180"},"PeriodicalIF":1.8,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141999528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pathologic Outcomes and Survival in Patients with Rectal Cancer and Increased Body Mass Index. 体质指数增高的直肠癌患者的病理结果和生存率
IF 1.8 3区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-01-01 Epub Date: 2024-08-23 DOI: 10.1159/000541085
Sameh Hany Emile, Giovanna Dasilva, Nir Horesh, Zoe Garoufalia, Rachel Gefen, Peige Zhou, Mariana Berho, Steven D Wexner

Introduction: We assessed the association between increased body mass index (BMI) and rectal cancer outcomes.

Methods: We included patients who underwent surgery for stage I-III rectal adenocarcinoma who were divided according to BMI at diagnosis: ideal BMI (18.5-24.9 kg/m2) and increased BMI (≥25 kg/m2). Groups were compared using univariate association analyses relative to baseline characteristics, pathologic outcomes, overall survival (OS), and disease-free survival (DFS). Main outcome measures involved circumferential resection margin (CRM), pathologic TNM stage, total mesorectal incision (TME) grade, OS, and DFS.

Results: 243 patients (64.6% male; median age 59 years) with a median BMI of 26.3 kg/m2 were included. 62.1% had BMI ≥25 kg/m2. Increased BMI patients had similar proportions of males (66.9% vs. 60.9%; p = 0.407) and comorbidities (ASA III: 47% vs. 37.4%; p = 0.24) to ideal BMI patients. There were no significant differences in cN1-2 stage (p = 0.279) or positive CRM (p = 0.062) rates. The groups had similar complete/near-complete TME, pathologic TN stage, and survival rates. Pathologic and survival outcomes were also similar with a BMI cutoff of 30.

Conclusions: There was a trend toward more nodal involvement in preoperative assessment and less CRM involvement in the final pathology of patients with increased BMI. Complete/near-complete TME and survival rates were comparable between the groups.

简介:我们评估了体重指数(BMI)增加与直肠癌预后之间的关系:我们评估了体重指数(BMI)增加与直肠癌预后之间的关系:我们纳入了接受手术治疗的 I-III 期直肠腺癌患者,并根据诊断时的体重指数对其进行了划分:理想体重指数(18.5-24.9 kg/m2)和增加体重指数(≥25 kg/m2)。通过单变量关联分析比较了各组的基线特征、病理结果、总生存期(OS)和无病生存期(DFS)。主要结果指标包括周缘切除缘(CRM)、病理TNM分期、总直肠间膜切口(TME)分级、OS和DFS。结果:共纳入243例患者(64.6%为男性;中位年龄59岁),中位体重指数(BMI)为26.3 kg/m2。62.1%的患者体重指数≥25 kg/m2。与理想体重指数患者相比,体重指数增加患者的男性比例(66.9% vs 60.9%;P=0.407)和合并症比例(ASA III:47% vs 37.4%;P=0.24)相似。cN1-2 期(p=0.279)或 CRM 阳性率(p=0.062)无明显差异。两组患者的完全/接近完全TME、病理TN分期和生存率相似。以 BMI 30.为界限,病理和生存结果也相似:结论:在术前评估中,BMI 增加的患者有更多结节受累的趋势,而在最终病理结果中,CRM 受累较少。两组患者的完全/近完全TME和生存率相当。
{"title":"Pathologic Outcomes and Survival in Patients with Rectal Cancer and Increased Body Mass Index.","authors":"Sameh Hany Emile, Giovanna Dasilva, Nir Horesh, Zoe Garoufalia, Rachel Gefen, Peige Zhou, Mariana Berho, Steven D Wexner","doi":"10.1159/000541085","DOIUrl":"10.1159/000541085","url":null,"abstract":"<p><strong>Introduction: </strong>We assessed the association between increased body mass index (BMI) and rectal cancer outcomes.</p><p><strong>Methods: </strong>We included patients who underwent surgery for stage I-III rectal adenocarcinoma who were divided according to BMI at diagnosis: ideal BMI (18.5-24.9 kg/m2) and increased BMI (≥25 kg/m2). Groups were compared using univariate association analyses relative to baseline characteristics, pathologic outcomes, overall survival (OS), and disease-free survival (DFS). Main outcome measures involved circumferential resection margin (CRM), pathologic TNM stage, total mesorectal incision (TME) grade, OS, and DFS.</p><p><strong>Results: </strong>243 patients (64.6% male; median age 59 years) with a median BMI of 26.3 kg/m2 were included. 62.1% had BMI ≥25 kg/m2. Increased BMI patients had similar proportions of males (66.9% vs. 60.9%; p = 0.407) and comorbidities (ASA III: 47% vs. 37.4%; p = 0.24) to ideal BMI patients. There were no significant differences in cN1-2 stage (p = 0.279) or positive CRM (p = 0.062) rates. The groups had similar complete/near-complete TME, pathologic TN stage, and survival rates. Pathologic and survival outcomes were also similar with a BMI cutoff of 30.</p><p><strong>Conclusions: </strong>There was a trend toward more nodal involvement in preoperative assessment and less CRM involvement in the final pathology of patients with increased BMI. Complete/near-complete TME and survival rates were comparable between the groups.</p>","PeriodicalId":11241,"journal":{"name":"Digestive Surgery","volume":" ","pages":"194-203"},"PeriodicalIF":1.8,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11506326/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142055172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recurrence of Hepatocellular Carcinoma after Liver Transplantation: Clinical Patterns and Hierarchy of Salvage Treatments. 肝移植后肝细胞癌复发:临床模式和挽救治疗的分级。
IF 1.8 3区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-01-01 Epub Date: 2024-09-05 DOI: 10.1159/000539460
Tommaso Giuliani, Eva Montalvá, Javier Maupoey, Andrea Boscá, Ana Hernando, David Calatayud, Vicente Navarro, Angel Rubín, Carmen Vinaixa, Rafael López-Andújar

Introduction: The multiparametric nature of recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT) still leads to uncertainty with its practical management. This study aims to characterize the main posttransplant recurrence patterns of HCC and to explore the therapeutic modalities targeting recurrence.

Methods: Consecutive patients who underwent LT for HCC at a single tertiary center were analyzed. The time from first recurrence to death was investigated for each site of presentation. The impact of each recurrence-targeted treatment on survival was studied.

Results: Of 660 patients with HCC, any recurrence occurred in 96 (15.4%) patients with a median time to recurrence of 20.0 months (95% CI: 15.6-23.8). Patients recurred across different patters including solitary distant locations (30.8%, n = 28), liver only (24.2%, n = 22), lung (18.7%, n = 17), multi-organ disease (17.6%, n = 16), and bone (8.8%, n = 8). Multi-organ and bone recurrences had the poorest survival, while solitary distant lesions and pulmonary recurrences had the best outcomes. Each treatment modality carried a distinctive survival.

Conclusions: Patients recurred across 3 patterns with different prognostic implications. The benefit of each treatment option on distinct recurrence patterns appears to be influenced by the biological behavior inherent in the recurrence pattern itself.

结构式摘要 引言:肝移植(LT)后肝细胞癌(HCC)复发的多参数特性仍导致其实际治疗的不确定性。本研究旨在描述 HCC 移植后的主要复发模式,并探讨针对复发的治疗方法:方法:分析了在一家三级中心接受LT治疗的HCC连续患者。对每个发病部位从首次复发到死亡的时间进行了调查。研究了每种针对复发的治疗方法对生存率的影响:在660名HCC患者中,96名(15.4%)患者出现复发,中位复发时间为20.0个月(95% CI 15.6-23.8)。患者的复发模式各不相同,包括单发远处复发(30.8%,n=28)、仅肝脏复发(24.2%,n=22)、肺复发(18.7%,n=17)、多器官疾病复发(17.6%,n=16)和骨复发(8.8%,n=8)。多器官和骨复发的生存率最差,而单发远处病灶和肺复发的生存率最好。每种治疗方式都有不同的生存率:患者的复发有三种模式,对预后的影响各不相同。每种治疗方案对不同复发模式的益处似乎受到复发模式本身固有的生物学行为的影响。
{"title":"Recurrence of Hepatocellular Carcinoma after Liver Transplantation: Clinical Patterns and Hierarchy of Salvage Treatments.","authors":"Tommaso Giuliani, Eva Montalvá, Javier Maupoey, Andrea Boscá, Ana Hernando, David Calatayud, Vicente Navarro, Angel Rubín, Carmen Vinaixa, Rafael López-Andújar","doi":"10.1159/000539460","DOIUrl":"10.1159/000539460","url":null,"abstract":"<p><strong>Introduction: </strong>The multiparametric nature of recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT) still leads to uncertainty with its practical management. This study aims to characterize the main posttransplant recurrence patterns of HCC and to explore the therapeutic modalities targeting recurrence.</p><p><strong>Methods: </strong>Consecutive patients who underwent LT for HCC at a single tertiary center were analyzed. The time from first recurrence to death was investigated for each site of presentation. The impact of each recurrence-targeted treatment on survival was studied.</p><p><strong>Results: </strong>Of 660 patients with HCC, any recurrence occurred in 96 (15.4%) patients with a median time to recurrence of 20.0 months (95% CI: 15.6-23.8). Patients recurred across different patters including solitary distant locations (30.8%, n = 28), liver only (24.2%, n = 22), lung (18.7%, n = 17), multi-organ disease (17.6%, n = 16), and bone (8.8%, n = 8). Multi-organ and bone recurrences had the poorest survival, while solitary distant lesions and pulmonary recurrences had the best outcomes. Each treatment modality carried a distinctive survival.</p><p><strong>Conclusions: </strong>Patients recurred across 3 patterns with different prognostic implications. The benefit of each treatment option on distinct recurrence patterns appears to be influenced by the biological behavior inherent in the recurrence pattern itself.</p>","PeriodicalId":11241,"journal":{"name":"Digestive Surgery","volume":" ","pages":"181-193"},"PeriodicalIF":1.8,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142139595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lymphocyte-to-Monocyte Ratio Predicts Survival for Intraductal Papillary Mucinous Neoplasm with Associated Invasive Carcinoma of the Pancreas: Results from a High-Volume Center. 淋巴细胞与单核细胞比率预测伴有胰腺浸润性癌的导管内乳头状黏液性肿瘤的生存率:一个高流量中心的研究结果。
IF 1.8 3区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-01-01 Epub Date: 2024-07-18 DOI: 10.1159/000540181
Ming Cui, Ya Hu, Bang Zheng, Tianqi Chen, Menghua Dai, Junchao Guo, Taiping Zhang, Jun Yu, Quan Liao, Yupei Zhao

Introduction: Intraductal papillary mucinous neoplasm (IPMN) is an important precursor lesion of pancreatic cancer. Systemic inflammatory parameters are widely used in the prognosis prediction of cancer; however, their prognostic implications in IPMN with associated invasive carcinoma (IPMN-INV) are unclear. This study aims to explore the prognostic value of systemic inflammatory parameters in patients with IPMN-INV.

Methods: From 2015 to 2021, patients with pathologically confirmed IPMN who underwent surgical resection at Peking Union Medical College Hospital were enrolled. The clinical, radiological, and pathological data of the enrolled patients were collected and analyzed. Preoperative systemic inflammatory parameters were calculated as previously reported.

Results: Eighty-six patients with IPMN-INV met the inclusion criteria. The lymphocyte-to-monocyte ratio (LMR) was the only systemic inflammatory parameter independently associated with the cancer-specific survival (CSS). An LMR higher than 3.5 was significantly associated with a favorable CSS in univariate (hazard ratio [HR] 0.305, p = 0.003) and multivariate analyses (HR 0.221, p = 0.001). Other independently prognostic factors included the presence of clinical symptoms, cyst size, N stage, and tumor differentiation. Additionally, a model including LMR was established for the prognosis prediction of IPMN-INV and had a C-index of 0.809.

Conclusions: Preoperative LMR could serve as a feasible prognostic biomarker for IPMN-INV. A decreased LMR (cutoff value of 3.5) was an independent predictor of poor survival for IPMN-INV.

背景:导管内乳头状粘液瘤(IPMN导管内乳头状粘液瘤(IPMN)是胰腺癌的重要前驱病变。全身炎症指标被广泛用于癌症的预后预测;然而,这些指标对伴有浸润性癌(IPMN-INV)的 IPMN 的预后影响尚不明确。本研究旨在探讨全身炎症指标在IPMN-INV患者中的预后价值:方法:2015 年至 2021 年,在北京协和医院接受手术切除的病理确诊 IPMN 患者入组。收集并分析入选患者的临床、放射学和病理学数据。术前全身炎症指标的计算方法与之前的报告相同:结果:86 例 IPMN-INV 患者符合纳入标准。淋巴细胞与单核细胞比值(LMR)是唯一与癌症特异性生存率(CSS)独立相关的全身炎症参数。在单变量分析(危险比 (HR) 0.305,P = 0.003)和多变量分析(HR 0.221,P = 0.001)中,LMR 高于 3.5 与良好的 CSS 显著相关。其他独立的预后因素包括临床症状、囊肿大小、N 分期和肿瘤分化。此外,还建立了一个包括 LMR 的 IPMN-INV 预后预测模型,其 C 指数为 0.809:结论:术前LMR可作为IPMN-INV可行的预后生物标志物。LMR下降(临界值为3.5)是IPMN-INV生存率低的独立预测因子。
{"title":"Lymphocyte-to-Monocyte Ratio Predicts Survival for Intraductal Papillary Mucinous Neoplasm with Associated Invasive Carcinoma of the Pancreas: Results from a High-Volume Center.","authors":"Ming Cui, Ya Hu, Bang Zheng, Tianqi Chen, Menghua Dai, Junchao Guo, Taiping Zhang, Jun Yu, Quan Liao, Yupei Zhao","doi":"10.1159/000540181","DOIUrl":"10.1159/000540181","url":null,"abstract":"<p><strong>Introduction: </strong>Intraductal papillary mucinous neoplasm (IPMN) is an important precursor lesion of pancreatic cancer. Systemic inflammatory parameters are widely used in the prognosis prediction of cancer; however, their prognostic implications in IPMN with associated invasive carcinoma (IPMN-INV) are unclear. This study aims to explore the prognostic value of systemic inflammatory parameters in patients with IPMN-INV.</p><p><strong>Methods: </strong>From 2015 to 2021, patients with pathologically confirmed IPMN who underwent surgical resection at Peking Union Medical College Hospital were enrolled. The clinical, radiological, and pathological data of the enrolled patients were collected and analyzed. Preoperative systemic inflammatory parameters were calculated as previously reported.</p><p><strong>Results: </strong>Eighty-six patients with IPMN-INV met the inclusion criteria. The lymphocyte-to-monocyte ratio (LMR) was the only systemic inflammatory parameter independently associated with the cancer-specific survival (CSS). An LMR higher than 3.5 was significantly associated with a favorable CSS in univariate (hazard ratio [HR] 0.305, p = 0.003) and multivariate analyses (HR 0.221, p = 0.001). Other independently prognostic factors included the presence of clinical symptoms, cyst size, N stage, and tumor differentiation. Additionally, a model including LMR was established for the prognosis prediction of IPMN-INV and had a C-index of 0.809.</p><p><strong>Conclusions: </strong>Preoperative LMR could serve as a feasible prognostic biomarker for IPMN-INV. A decreased LMR (cutoff value of 3.5) was an independent predictor of poor survival for IPMN-INV.</p>","PeriodicalId":11241,"journal":{"name":"Digestive Surgery","volume":" ","pages":"111-121"},"PeriodicalIF":1.8,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11382638/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141562935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Surgery versus Endoscopy for the Management of Painful Chronic Pancreatitis: A Systematic Review and Meta-Analysis of Randomized Trials. 手术与内镜治疗疼痛性慢性胰腺炎:随机试验的系统回顾和元分析》。
IF 1.8 3区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-01-01 Epub Date: 2024-01-08 DOI: 10.1159/000535588
Noel Cassar, Paul Cromwell, Sinead Duggan, Charlotte van Veldhuisen, Marja Boermeester, Marc Besselink, Kevin Conlon

Background: Debate exists regarding the optimal treatment for painful chronic pancreatitis (CP). This meta-analysis aims to determine the outcomes of surgical intervention as compared to endoscopy in patients with painful CP.

Methods: A systematic review and meta-analysis including studies from PubMed, Embase, Web of Science, and Cochrane Databases (1995 onwards) was done by two independent reviewers using PRISMA guidelines. Primary outcome was pain relief.

Results: Among 8,479 studies, three were randomized trials, comprising a total of 199 patients. Compared with endoscopy, surgery was associated with a lower Izbicki score, both at medium term (mean difference (MD) 21.46, 95% confidence interval (CI) 13.48-29.43, p < 0.00001) and long term (MD: 17.80, 95% CI: 8.36-27.23, p = 0.0002). A higher proportion of surgical patients had some sort of pain relief compared with those who had endoscopy, both at medium term (72% vs. 46%, RR: 1.51, 95% CI: 1.19-1.90, p = 0.0006) and long term (73% vs. 47%, RR: 1.50, 95% CI: 1.19-1.89, p = 0.0007). Complete pain relief was more common in the surgical group compared to the endoscopy group, both at medium term (33% vs. 17%, RR: 1.97, 95% CI: 1.16-3.36, p = 0.01) and long term (35% vs. 18%, RR: 1.92, 95% CI: 1.15-3.20, p = 0.01). The pooled crossover rate from endoscopy to surgery was 22% (22/99).

Conclusions: Surgical treatment in patients with painful CP leads to better pain control, requiring fewer interventions as compared to endoscopic treatment.

背景:关于慢性胰腺炎(CP)疼痛的最佳治疗方法存在争议:关于疼痛性慢性胰腺炎(CP)的最佳治疗方法存在争议:本荟萃分析旨在确定疼痛性慢性胰腺炎患者手术治疗与内窥镜检查的疗效比较:方法:两位独立审稿人采用 PRISMA 指南对 PubMed、Embase、Web of Science 和 Cochrane 数据库(1995 年以后)中的研究进行了系统回顾和荟萃分析。主要结果是疼痛缓解:在8479项研究中,有三项是随机试验,共涉及199名患者。与内窥镜检查相比,手术治疗与较低的 Izbicki 评分相关,中期(平均差 (MD) 21.46,95% 置信区间 (CI)13.48-29.43,P 结论:手术治疗对疼痛性颅内压增高患者的疗效更佳:与内窥镜治疗相比,疼痛型 CP 患者的手术治疗能更好地控制疼痛,所需的干预措施也更少。
{"title":"Surgery versus Endoscopy for the Management of Painful Chronic Pancreatitis: A Systematic Review and Meta-Analysis of Randomized Trials.","authors":"Noel Cassar, Paul Cromwell, Sinead Duggan, Charlotte van Veldhuisen, Marja Boermeester, Marc Besselink, Kevin Conlon","doi":"10.1159/000535588","DOIUrl":"10.1159/000535588","url":null,"abstract":"<p><strong>Background: </strong>Debate exists regarding the optimal treatment for painful chronic pancreatitis (CP). This meta-analysis aims to determine the outcomes of surgical intervention as compared to endoscopy in patients with painful CP.</p><p><strong>Methods: </strong>A systematic review and meta-analysis including studies from PubMed, Embase, Web of Science, and Cochrane Databases (1995 onwards) was done by two independent reviewers using PRISMA guidelines. Primary outcome was pain relief.</p><p><strong>Results: </strong>Among 8,479 studies, three were randomized trials, comprising a total of 199 patients. Compared with endoscopy, surgery was associated with a lower Izbicki score, both at medium term (mean difference (MD) 21.46, 95% confidence interval (CI) 13.48-29.43, p &lt; 0.00001) and long term (MD: 17.80, 95% CI: 8.36-27.23, p = 0.0002). A higher proportion of surgical patients had some sort of pain relief compared with those who had endoscopy, both at medium term (72% vs. 46%, RR: 1.51, 95% CI: 1.19-1.90, p = 0.0006) and long term (73% vs. 47%, RR: 1.50, 95% CI: 1.19-1.89, p = 0.0007). Complete pain relief was more common in the surgical group compared to the endoscopy group, both at medium term (33% vs. 17%, RR: 1.97, 95% CI: 1.16-3.36, p = 0.01) and long term (35% vs. 18%, RR: 1.92, 95% CI: 1.15-3.20, p = 0.01). The pooled crossover rate from endoscopy to surgery was 22% (22/99).</p><p><strong>Conclusions: </strong>Surgical treatment in patients with painful CP leads to better pain control, requiring fewer interventions as compared to endoscopic treatment.</p>","PeriodicalId":11241,"journal":{"name":"Digestive Surgery","volume":" ","pages":"1-11"},"PeriodicalIF":1.8,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139402283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Vagal Sparing Gastrectomy: A Systematic Review and Meta-Analysis. 迷走神经保留胃切除术:系统回顾和荟萃分析。
IF 1.8 3区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-01-01 Epub Date: 2024-02-27 DOI: 10.1159/000536472
Ashraf M Tokhi, Sam V George, Carlos S Cabalag, David S Liu, Cuong P Duong

Introduction: Radical gastrectomy is associated with significant functional complications. In appropriate patients may be amenable to less invasive resection aimed at preserving the vagal trunks. The aim of this systematic review and meta-analysis was to assess the functional consequences and oncological safety of vagal sparing gastrectomy (VSG) compared to conventional non-vagal sparing gastrectomy (CG).

Methods: A systematic review of four databases in accordance with PRISMA guidelines was undertaken for studies published between January 1, 1990, and December 15, 2021, comparing patients who underwent VSG to CG. We meta-analysed the following outcomes: operative time, blood loss, nodal yield, days to flatus, body weight changes, as well as the incidence of post-operative cholelithiasis, diarrhoea, delayed gastric emptying, and dumping syndrome.

Results: Thirty studies were included in the meta-analysis with a selection of studies qualitatively analysed. VSG was associated with a lower rate of cholelithiasis (OR: 0.25, 95% CI: 0.15-0.41, p < 0.010) and early dumping syndrome (OR: 0.42, 95% CI: 0.21-0.86; p = 0.02), less blood loss (mean difference [MD]: -51 mL, 95% CI: -89.11 to -12.81 mL, p = 0.009), less long-term weight loss (MD: 2.03%, 95% CI: 0.31-3.76%, p = 0.02) and a faster time to flatus (MD: -0.42 days, 95% CI: -0.48 to 0.36, p < 0.001). There was no significant difference in nodal harvest, overall survival, and all other endpoints.

Conclusion: VSG significantly reduces the incidence of post-operative cholelithiasis and dumping syndrome, decreases weight loss, and facilitates an earlier return of gut motility. Although technically more challenging, VSG should be considered for prophylactic surgery.

根治性胃切除术与严重的功能性并发症有关。在适当的情况下,患者可以采用旨在保留迷走神经干的微创切除术。本系统综述和荟萃分析旨在评估迷走神经保留胃切除术(VSG)与传统非迷走神经保留胃切除术(CG)相比的功能性后果和肿瘤安全性。我们对四个数据库中发表于 1990 年 11 月 1 日至 2021 年 12 月 15 日之间的研究进行了系统性回顾,比较了接受 VSG 和 CG 的患者。我们对以下结果进行了荟萃分析:手术时间、失血量、结节率、排气天数、体重变化以及术后胆石症、腹泻、胃排空延迟和倾倒综合征的发生率。荟萃分析纳入了 30 项研究,并对部分研究进行了定性分析。VSG 与较低的胆石症发生率相关(OR 0.25,95% CI 0.15-0.41, p
{"title":"Vagal Sparing Gastrectomy: A Systematic Review and Meta-Analysis.","authors":"Ashraf M Tokhi, Sam V George, Carlos S Cabalag, David S Liu, Cuong P Duong","doi":"10.1159/000536472","DOIUrl":"10.1159/000536472","url":null,"abstract":"<p><strong>Introduction: </strong>Radical gastrectomy is associated with significant functional complications. In appropriate patients may be amenable to less invasive resection aimed at preserving the vagal trunks. The aim of this systematic review and meta-analysis was to assess the functional consequences and oncological safety of vagal sparing gastrectomy (VSG) compared to conventional non-vagal sparing gastrectomy (CG).</p><p><strong>Methods: </strong>A systematic review of four databases in accordance with PRISMA guidelines was undertaken for studies published between January 1, 1990, and December 15, 2021, comparing patients who underwent VSG to CG. We meta-analysed the following outcomes: operative time, blood loss, nodal yield, days to flatus, body weight changes, as well as the incidence of post-operative cholelithiasis, diarrhoea, delayed gastric emptying, and dumping syndrome.</p><p><strong>Results: </strong>Thirty studies were included in the meta-analysis with a selection of studies qualitatively analysed. VSG was associated with a lower rate of cholelithiasis (OR: 0.25, 95% CI: 0.15-0.41, p &lt; 0.010) and early dumping syndrome (OR: 0.42, 95% CI: 0.21-0.86; p = 0.02), less blood loss (mean difference [MD]: -51 mL, 95% CI: -89.11 to -12.81 mL, p = 0.009), less long-term weight loss (MD: 2.03%, 95% CI: 0.31-3.76%, p = 0.02) and a faster time to flatus (MD: -0.42 days, 95% CI: -0.48 to 0.36, p &lt; 0.001). There was no significant difference in nodal harvest, overall survival, and all other endpoints.</p><p><strong>Conclusion: </strong>VSG significantly reduces the incidence of post-operative cholelithiasis and dumping syndrome, decreases weight loss, and facilitates an earlier return of gut motility. Although technically more challenging, VSG should be considered for prophylactic surgery.</p>","PeriodicalId":11241,"journal":{"name":"Digestive Surgery","volume":" ","pages":"147-160"},"PeriodicalIF":1.8,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139982554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Novel Method Using Gadolinium-Ethoxybenzyl Diethylenetriamine Pentaacetate Acid-Enhanced Magnetic Resonance Imaging for Predicting Post-Hepatectomy Liver Failure in Hepatocellular Carcinoma Patients with a Major Portal Vein Tumor Thrombus. 利用钆-乙氧基苄基二乙烯三胺五乙酸增强磁共振成像预测伴有主要门静脉肿瘤血栓的肝细胞癌患者肝切除术后肝功能衰竭的新方法。
IF 2.7 3区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-01-01 Epub Date: 2024-01-12 DOI: 10.1159/000536157
Kosuke Nishio, Shohei Komatsu, Keitaro Sofue, Masahiro Kido, Kaori Kuramitsu, Hidetoshi Gon, Kenji Fukushima, Takeshi Urade, Hiroaki Yanagimoto, Hirochika Toyama, Takumi Fukumoto

Introduction: The usefulness of gadolinium-ethoxybenzyl diethylenetriamine pentaacetate acid-enhanced magnetic resonance imaging (EOB-MRI) in assessing the functional future remnant liver volume (fFRLV) to predict post-hepatectomy liver failure (PHLF) has been previously reported. Herein, we evaluated the efficacy of this technique in patients with hepatocellular carcinoma (HCC) with a major portal vein tumor thrombus (PVTT).

Methods: This study included 21 patients with PVTT in the ipsilateral first-order branch (Vp3) and 30 patients with PVTT in the main trunk/contralateral branch (Vp4). To evaluate fFRLV, the signal intensity (SI) of the remnant liver was determined on T1-weighted images, using both conventional and newly developed methods. The fFRLV was calculated using the SI of the remnant liver and muscle, remnant liver volume, and body surface area. Preoperative factors predicting PHLF (≥grade B) in HCC patients with Vp3/4 PVTT were evaluated.

Results: In the Vp3 group, we found fFRLV area under the receiver-operating characteristic curves (AUCs) above 0.70 (AUC = 0.875, 0.750) using EOB-MRI results calculated using either the plot or whole method. None of the parameters in the Vp4 group had an AUC greater than 0.70.

Conclusion: The fFRLV calculated by EOB-MRI using the whole method can be as useful as the conventional method in predicting PHLF (≥grade B) for HCC patients with Vp3 PVTT.

介绍:钆-乙氧基苄基二乙烯三胺五醋酸增强磁共振成像(EOB-MRI)可用于评估未来功能性残肝体积(fFRLV),从而预测肝切除术后肝功能衰竭(PHLF)。在此,我们评估了该技术在伴有主要门静脉肿瘤血栓(PVTT)的肝细胞癌(HCC)患者中的疗效:本研究包括 21 例同侧一阶分支(Vp3)PVTT 患者和 30 例主干/对侧分支(Vp4)PVTT 患者。为了评估 fFRLV,采用传统和新开发的方法在 T1 加权图像上确定残肝的信号强度(SI)。利用残肝和肌肉的 SI、残肝体积和体表面积计算 fFRLV。评估了预测Vp3/4 PVTT HCC患者PHLF(≥B级)的术前因素:在 Vp3 组中,我们发现使用绘图法或整体法计算的 EOB-MRI 结果的 fFRLV AUC 超过 0.70(AUC = 0.875,0.750)。Vp4组中没有一个参数的AUC大于0.70:结论:在预测 Vp3 PVTT 的 HCC 患者的 PHLF(≥B 级)时,使用整体法计算的 EOB-MRI fFRLV 与传统方法一样有用。
{"title":"A Novel Method Using Gadolinium-Ethoxybenzyl Diethylenetriamine Pentaacetate Acid-Enhanced Magnetic Resonance Imaging for Predicting Post-Hepatectomy Liver Failure in Hepatocellular Carcinoma Patients with a Major Portal Vein Tumor Thrombus.","authors":"Kosuke Nishio, Shohei Komatsu, Keitaro Sofue, Masahiro Kido, Kaori Kuramitsu, Hidetoshi Gon, Kenji Fukushima, Takeshi Urade, Hiroaki Yanagimoto, Hirochika Toyama, Takumi Fukumoto","doi":"10.1159/000536157","DOIUrl":"10.1159/000536157","url":null,"abstract":"<p><strong>Introduction: </strong>The usefulness of gadolinium-ethoxybenzyl diethylenetriamine pentaacetate acid-enhanced magnetic resonance imaging (EOB-MRI) in assessing the functional future remnant liver volume (fFRLV) to predict post-hepatectomy liver failure (PHLF) has been previously reported. Herein, we evaluated the efficacy of this technique in patients with hepatocellular carcinoma (HCC) with a major portal vein tumor thrombus (PVTT).</p><p><strong>Methods: </strong>This study included 21 patients with PVTT in the ipsilateral first-order branch (Vp3) and 30 patients with PVTT in the main trunk/contralateral branch (Vp4). To evaluate fFRLV, the signal intensity (SI) of the remnant liver was determined on T1-weighted images, using both conventional and newly developed methods. The fFRLV was calculated using the SI of the remnant liver and muscle, remnant liver volume, and body surface area. Preoperative factors predicting PHLF (≥grade B) in HCC patients with Vp3/4 PVTT were evaluated.</p><p><strong>Results: </strong>In the Vp3 group, we found fFRLV area under the receiver-operating characteristic curves (AUCs) above 0.70 (AUC = 0.875, 0.750) using EOB-MRI results calculated using either the plot or whole method. None of the parameters in the Vp4 group had an AUC greater than 0.70.</p><p><strong>Conclusion: </strong>The fFRLV calculated by EOB-MRI using the whole method can be as useful as the conventional method in predicting PHLF (≥grade B) for HCC patients with Vp3 PVTT.</p>","PeriodicalId":11241,"journal":{"name":"Digestive Surgery","volume":" ","pages":"30-36"},"PeriodicalIF":2.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139466226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Intracorporeal versus Extracorporeal Anastomosis in Laparoscopic Right Hemicolectomy: An Updated Systematic Review and Meta-Analysis of Randomized Control Trials. 腹腔镜右半结肠切除术中的体腔内吻合与体外吻合:随机对照试验的最新系统回顾和 Meta 分析》。
IF 1.8 3区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-01-01 Epub Date: 2024-09-27 DOI: 10.1159/000541373
Pengyu Wei, Yang Li, Jiale Gao, Si Wu, Wenlong Shu, Hongwei Yao, Zhongtao Zhang

Introduction: Laparoscopic right hemicolectomy has become the standard surgical procedure for the treatment of right colon disease; however, the choice of anastomosis remains controversial. This study aimed to compare the safety and efficacy of intracorporeal anastomosis and extracorporeal anastomosis in laparoscopic right hemicolectomy.

Methods: A systematic literature search was performed in PubMed, Embase, Web of Science, and Cochrane Library. Randomized controlled trials that compared intracorporeal anastomosis with extracorporeal anastomosis in patients with laparoscopic right hemicolectomy until June 4, 2023, are selected. The primary outcomes measured were incidence of anastomotic leakage within 30 days post-operation. Statistical analyses were performed using Review Manager (version 5.4.1).

Results: Seven RCTs, including 720 patients, were eligible for the meta-analysis. The incidence of anastomotic leakage showed no significant difference between the intracorporeal anastomosis group and the extracorporeal anastomosis group (RR 0.93, 95% CI: 0.49, 1.76, p = 0.83, and I2 = 0%). However, the intracorporeal anastomosis group had significantly lower rates of postoperative ileus (RR 0.67, 95% CI: 0.45-0.99, p = 0.04, I2 = 46%) and surgical site infections (RR 0.34, 95% CI: 0.16-0.74, p = 0.007, I2 = 0%) compared to the extracorporeal anastomosis group. Additionally, patients in the intracorporeal anastomosis group experienced earlier postoperative passage of gas and stool (WMD -0.39, 95% CI: -0.60, -0.19, p = 0.0002, and I2 = 67%; WMD -0.53, 95% CI: -0.85, -0.21, p = 0.001, and I2 = 75%), as well as shorter hospital stays (WMD -0.46, 95% CI: -0.74, -0.18, p = 0.001, and I2 = 34%).

Conclusion: In laparoscopic right hemicolectomy, intracorporeal anastomosis does not increase the incidence of anastomotic leakage within 30 days post-operation compared to extracorporeal anastomosis. In addition, intracorporeal anastomosis resulted in faster recovery of bowel function. This suggests that intracorporeal anastomosis is safe and effective.

简介:腹腔镜右半结肠切除术是治疗右半结肠疾病的标准方法,但对于选择体腔内吻合术还是体腔外吻合术仍存在争议。本研究比较了两者的安全性和有效性。方法 截至 2023 年 6 月 4 日,我们在 PubMed、Embase、Web of Science 和 Cochrane Library 中对比较腹腔镜右半结肠切除术中这两种吻合技术的随机对照试验进行了系统检索。主要结果是30天内的吻合口渗漏。使用Review Manager(5.4.1版)进行统计分析。结果 共纳入 7 项研究,涉及 720 名患者。各组间吻合口漏率无明显差异(RR 0.93,95% CI 0.49-1.76,P=0.83)。不过,体腔内吻合术的术后回肠梗阻率(RR 0.67,95% CI 0.45-0.99;P=0.04)和手术部位感染率(RR 0.34,95% CI 0.16-0.74;P=0.007)较低。采用体腔内吻合术的患者肠道功能恢复更快(气体通过率:WMD -0.39,p=0.0002;粪便通过率:WMD -0.53,p=0.001),住院时间更短(WMD -0.46,p=0.001)。结论 与体外吻合术相比,体外吻合术不会增加吻合口漏的风险,并能促进肠道更快恢复。它是一种安全有效的选择。
{"title":"Intracorporeal versus Extracorporeal Anastomosis in Laparoscopic Right Hemicolectomy: An Updated Systematic Review and Meta-Analysis of Randomized Control Trials.","authors":"Pengyu Wei, Yang Li, Jiale Gao, Si Wu, Wenlong Shu, Hongwei Yao, Zhongtao Zhang","doi":"10.1159/000541373","DOIUrl":"10.1159/000541373","url":null,"abstract":"<p><strong>Introduction: </strong>Laparoscopic right hemicolectomy has become the standard surgical procedure for the treatment of right colon disease; however, the choice of anastomosis remains controversial. This study aimed to compare the safety and efficacy of intracorporeal anastomosis and extracorporeal anastomosis in laparoscopic right hemicolectomy.</p><p><strong>Methods: </strong>A systematic literature search was performed in PubMed, Embase, Web of Science, and Cochrane Library. Randomized controlled trials that compared intracorporeal anastomosis with extracorporeal anastomosis in patients with laparoscopic right hemicolectomy until June 4, 2023, are selected. The primary outcomes measured were incidence of anastomotic leakage within 30 days post-operation. Statistical analyses were performed using Review Manager (version 5.4.1).</p><p><strong>Results: </strong>Seven RCTs, including 720 patients, were eligible for the meta-analysis. The incidence of anastomotic leakage showed no significant difference between the intracorporeal anastomosis group and the extracorporeal anastomosis group (RR 0.93, 95% CI: 0.49, 1.76, p = 0.83, and I2 = 0%). However, the intracorporeal anastomosis group had significantly lower rates of postoperative ileus (RR 0.67, 95% CI: 0.45-0.99, p = 0.04, I2 = 46%) and surgical site infections (RR 0.34, 95% CI: 0.16-0.74, p = 0.007, I2 = 0%) compared to the extracorporeal anastomosis group. Additionally, patients in the intracorporeal anastomosis group experienced earlier postoperative passage of gas and stool (WMD -0.39, 95% CI: -0.60, -0.19, p = 0.0002, and I2 = 67%; WMD -0.53, 95% CI: -0.85, -0.21, p = 0.001, and I2 = 75%), as well as shorter hospital stays (WMD -0.46, 95% CI: -0.74, -0.18, p = 0.001, and I2 = 34%).</p><p><strong>Conclusion: </strong>In laparoscopic right hemicolectomy, intracorporeal anastomosis does not increase the incidence of anastomotic leakage within 30 days post-operation compared to extracorporeal anastomosis. In addition, intracorporeal anastomosis resulted in faster recovery of bowel function. This suggests that intracorporeal anastomosis is safe and effective.</p>","PeriodicalId":11241,"journal":{"name":"Digestive Surgery","volume":" ","pages":"224-244"},"PeriodicalIF":1.8,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142343559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Digestive Surgery
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1